West Pharma (NYSE: WST) reported Q3 EPS of $1.96, $0.27 better than the analyst estimate of $1.69. Revenue for the quarter came in at $804.6 million versus the consensus estimate of $786.33 million.

GUIDANCE:

West Pharma sees Q4 2025 EPS of $1.81-$1.86, versus the consensus of $1.78. West Pharma sees Q4 2025 revenue of $790-800 million, versus the consensus of $796.4 million.

West Pharma sees FY2025 EPS of $7.06-$7.11, versus the consensus of $6.78. West Pharma sees FY2025 revenue of $3.06-3.07 billion, versus the consensus of $3.049 billion.

For earnings history and earnings-related data on West Pharma (WST) click here.